Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-01

Study Completion Date

2021-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration. It also increases microvascular permeability. If the VEGFs have proven their efficiency in the decrease of choroidal neovascular proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown. Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have an incidence on the loss of retinal nerve fibers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

NCT00709657

Macular Degeneration Regional Blood Flow Vascular Endothelial Growth Factor

TERMINATED NA

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

NCT03940690

Retinal Telangiectasis Coats Disease

TERMINATED PHASE3

Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration

NCT03680326

Vitreomacular Interface

COMPLETED

Intravitreal Bevacizumab for Diabetic Retinopathy

NCT00600262

Severe Nonproliferative Proliferative Diabetic Retinopathy Active Photocoagulated Diabetic Retinopathy

TERMINATED PHASE2/PHASE3

Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

NCT06243406

Choroidal Neovascularization

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Neovascularization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with anti-VEGF

Gonioscopy

Intervention Type DEVICE

Study of the trabecular structure by gonioscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gonioscopy

Study of the trabecular structure by gonioscopy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years old
* Patients treated with anti-VEGF according to the French summary of product characteristics (SPC)
* Patients who have been informed of the trial and who are not opposed to participate in the study

Exclusion Criteria

* Patients presenting a retinal condition, including the optic nerve
* Patients treated with anti-VEGF in both eyes
* Pregnant women
* Lack of affiliation to social security or universal health coverage

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No